Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 701–780 of 780
Lourenço, Ó. D., Marques, F. B., Carrasco, J., & Inês, M. S. (2012) · Revista portuguesa de farmacoterapia · doi:10.25756/rpf.v4i4.60
Tapson, V. F. (2012) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e318250b5de
Newer anticoagulants for the prevention of venous thromboembolism.
Jaggia, A. (2012) · PubMed
Thromboprophylaxis after total hip arthroplasty
Friedman, R. J. (2012) · Current Orthopaedic Practice · doi:10.1097/bco.0b013e3182597bef
“34.(27) Overall, ADVANCE 3 demonstrated the status of apixaban as a promising agent”
BackgroundInfluentialPrevention of Venous Thromboembolism
Rose, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-22602-6_6
Frade, G., & Javier, L. (2014) · University of Valladolid Documentary Repository (University of Valladolid)
Anticoagulants oraux directs : quels facteurs de risque d'une concentration plasmatique élevée ?
Mutte, F.-A. (2016) · HAL · Cited by 1
(2016) · Wiley eBooks · doi:10.1002/9781119039112.ch107
Prevenzione della tromboembolia venosa in ambiente chirurgico
Degirmenci, S.-E., Tacquard, C. A., & Steib, A. (2016) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(16)78784-6
Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes
Sharda, A. V., & Zwicker, J. I. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_44
Russian Experience of the Rational Thromboprophylaxis in Traumatology and Orthopaedics
Анатольевич, Ф. С., Andrey, L., & Rudolf, M. (2016) · Journal of Pharmacy and Pharmacology · doi:10.17265/2328-2150/2016.04.002
“Requirements to the current anticoagulant drugs, are the follows: the drug should provide high efficacy along with a low risk of bleeding, ease of use (oral, no need for dosage adjustments and special monitoring), safety (may be administered in elderly patients with renal insufficiency, hepatic insufficiency) and conv…”
BackgroundНапроксен: нова стратегія зниження серцево-судинного ризику нестероїдних протизапальних препаратів
Svyrydova, N. K. (2016) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.5.83.2016.78478
Los nuevos anticoagulantes orales
Roca, R. A. (2016) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2016.02.010
A Revolution in VTE Prophylaxis
Calderon, A. J., & FACP., F. (2010) · Journal watch · doi:10.1056/hm201012220000001
New Anticoagulants for Venous Thromboembolism
Green, D. (2011) · Journal watch · doi:10.1056/oh201102080000001
Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants
Vornicu, O., Larock, A., Douxfils, J., Mullier, F., Dubois, V., Gourdin, M. J., Lessire, S., & Dincq, A.-S. (2016) · EMJ Hematology · doi:10.33590/emjhematol/10312079
Bahloul, M., Regaieg, K., Chtara, K., Turki, O., Baccouch, N., Chaari, A., & Bouaziz, M. (2017) · Journal Européen des Urgences et de Réanimation · doi:10.1016/j.jeurea.2017.04.004
Lieberman, J. R., & Alluri, R. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-54913-2_6
Clinical and Economic Outcomes of New Oral Anticoagulants in Orthopaedics
Lakić, D., Travica, J., Odalović, M., & Tadić, I. (2017) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2017-0066
“ADVANCE-1 (13) and ADVANCE-2 (14) studies have evaluated the use of apixaban in patients who underwent elective knee replacement surgery, while the ADVANCE-3 study (15) evaluated the effects in patients who underwent elective hip replacement surgery.”
BackgroundMethodDirect oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases
Tomić, M., Novakovic, A., Milojević, P. S., Nenezić, D., Stojanovic, I. C., & Gajin, P. (2017) · Medicinski casopis · doi:10.5937/mckg51-15563
Hockett, J. (2017) · Orthopedic Research Online Journal · doi:10.31031/oproj.2017.01.000503
Stoberock, K., Larena-Avellaneda, A. A., Kölbel, T., Atlihan, G., Rohlffs, F., Behrendt, C., & Debus, E. S. (2018) · Gefässchirurgie · doi:10.1007/s00772-018-0362-3
Risk of Venous Thromboembolism in Surgical Elderly Patients
Falanga, A., & Milesi, V. (2018) · Springer eBooks · doi:10.1007/978-3-319-60861-7_5
Venous thromboembolism (post-surgery)
Romualdi, E., & Ageno, W. (2012) · doi:10.2217/ebo.12.34
Borgen, P. O. (2018) · NORA - Norwegian Open Research Archives
Mitic, G. P. (2014) · Srce i krvni sudovi · doi:10.5937/siks1403188m
Roman, F., Allen, J.-S. P., Wurm, H., & MacLaughlin, K. L. (2018) · Journal of Primary Care & Community Health · doi:10.1177/2150132718797446
Hepatotoxicity of New Oral Anticoagulants
Kasimova, A. R., Philippova, A. V., & Колбин, А. С. (2018) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2018-14-4-621-628
Belov, M. V. (2018) · N N Priorov Journal of Traumatology and Orthopedics · doi:10.17816/vto201825147-51 · Cited by 1
Pharmacological Treatment of Venous Disorders
Kalodiki, E., & Fareed, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_223-1
Кочетков, А. И., & Ostroumova, O. D. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-4-593-603
Venous Disorders: Medical Management
Kalodiki, E., & Fareed, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_223
Green, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818781-4.00003-0
Updates on the use of direct oral anticoagulants for the management of chronic conditions
Gibson, C. M. (2020) · Pharmacy Today · doi:10.1016/j.ptdy.2020.11.019
Revista Española de Cirugía Ortopédica y Traumatología
Castellet, E., & Otero, R. (2016)
Gombár, C. (2021) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10900
“There are studies that compared the efficacy of apixaban versus enoxaparin that led to the approval of apixaban for VTE prophylaxis after major orthopaedic interventions [40, 41] The current recommended dosage for VTE prophylaxis after THR is 2.”
BackgroundPerioperativer Umgang mit modernen oralen Antikoagulanzien in der Herzchirurgie
Meyer, A., Kempfert, J., Arsalan, M., & Walther, T. (2014) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-014-1120-9
“Indiziert ist Apixaban: F zur Prophylaxe venöser Thromboembolien nach elektivem Hüft- und Kniegelenkersatz [31, 32, 33], F zur Prävention eines thrombembolischen Schlaganfalls, F zur Therapie der Lungenembolie bzw.”
BackgroundMora, R. M., & Amado, E. (2012) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(12)70282-7
Apixaban (Eliquis®) : nouvel anticoagulant oral
Fourcade, M. (2012) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(12)70415-7
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00013-3
Bernad, R. V. (2012) · Revista Clínica Española · doi:10.1016/s0014-2565(12)70009-7
Krain, A. B. (2018) · Springer eBooks · doi:10.1007/978-3-319-72228-3_5
Anticoagulants and antithrombotics in critical illness
McDonald, V., & Scully, M. (2016) · doi:10.1093/med/9780199600830.003.0051
Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?
Samama, C. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77846-6.00046-x
Jayaram, K. (2022) · Springer eBooks · doi:10.1007/978-981-19-0954-2_38
Thromboprophylaxis in Urological and Andrological Surgery (Review article)
Зайцев, В. І. (2022) · Health of Man · doi:10.30841/2307-5090.1-2.2022.263915
“Some nonurological studies have, however, suggested that prophylaxis can begin 24 hours after surgery without an increase in VTE but with a decrease in bleeding complications [9, 10].”
BackgroundWhich Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?
Samama, C. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2768-1.00035-x
Чегуров, О. К., & Стогов, М. В. (2023) · Современные проблемы науки и образования · doi:10.17513/spno.32649
Microcirculation - Updates in the Next Frontier of Vascular Disease
Kibel, A., & Firstenberg, M. S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001544
Direct oral anticoagulants in general practice
Gee, E. (2023) · Practice Nursing · doi:10.12968/pnur.2023.34.8.300
Souza, D. H. I., de Almeida, N. A., Domingues, M. L. D. P., Baldoni, A. O., Baldoni, N. R., & Rios, D. R. A. (2023) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2023.196548
DOACs for the Medical Management of Venous Thromboembolism in Adults
Kommu, S., & Arepally, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112581
Prevention and treatment of venous thromboembolic complications in orthopedic patients
Trofimov, N. A., Николаев, Н. С., Babokin, V. E., Drandrov, R. N., Khripunov, S. A., Nikolsky, A. V., Edkov, A. V., & Федоров, С. А. (2024) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia202402152
Efficacy and Safety of Apixaban and Enoxaparin for Thromboprophylaxis after Total Hip Arthroplasty
Xiao, W., Ye, M., Huang, J., Cao, Y., & Cao, X. (2024) · MEDS Clinical Medicine · doi:10.23977/medsc.2024.050220
“Currently, low molecular heparin and sulphadoxine need to be injected subcutaneously; for prolonged use; and after hip surgery[2].”
BackgroundThe Use of Apixaban for Postoperative Venous Thromboembolism Prophylaxis in Gynecologic Cancer
Knisely, A. T., & Fleming, N. D. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15512-5
Thromboprophylaxie périopératoire en chirurgie urologique
Peyrottes, A., Depaquit, T. L., & Dariane, C. (2024) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2024.05.001
Al-najjar, B. Y., Abbas, I. K., & Ghareeb, M. M. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v7i2.1402
Faktor-XI-Hemmer in der Neurologie
Diener, H., Endres, M., & Nolte, C. H. (2024) · Neurologie up2date · doi:10.1055/a-2337-9762
Pharmacological prophylaxis of venous thromboembolism in surgical patients
Savoliuk, S. I., & Bondarenko, L. B. (2025) · EMERGENCY MEDICINE · doi:10.22141/2224-0586.20.8.2024.1803
Venous Thromboembolic Prophylaxis in Revision Hip Arthroplasty
Hudson, P. W., Siljander, M. P., & Nassif, N. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-83959-7_64
A COMPREHENSIVE REVIEW ON DOSAGE FORM FOR ANTICOAGULANT DRUG
NAVGHARE, M. M., Kulkarni, N. S., & Deshmukh, V. (2025) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2025v17i6.7068
Stevens, C. A., Dell’Orfano, H., Reardon, D. P., Matta, L. S., Greenwood, B. C., & Atay, J. K. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0079-5
Mattiozzi, M. (2022) · Electronic Theses and Dissertations Repository (University of Pisa)
Omer, A. A. A., Csatordai, M., Viola, R., & Doró, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1770826
“…extending from cardiovascular indications to include prophylaxis of VTE in patients undergoing orthopedic surgery, emphasizing their growing importance in routine clinical practice (Turpie et al., 2009; Beyer-Westendorf et al., 2017; Fuji et al., 2014; Lassen et al., 2010a; Lassen et al., 2010b).”
Black, K. A., Mateshaytis, J., Sevick, L. K., Rogers, J., Bisch, S. P., Flasha, P., & Pin, S. (2026) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2026.102056
“…evidence supporting the use of DOACs for post-operative extended VTE prophylaxis in the gynecologic oncology population (Stewart et al., 2024; Lassen et al., 2010; Lassen et al., 2010; Guntupalli et al., 2020) our centers elected to initiate a transition from LMWH (tinzaparin) to DOAC (apixaban).”
Prescription des antithrombotiques oraux chez l’adulte en médecine de ville
Zerah, L. (2020) · theses.fr (ABES) · doi:10.70675/89ac2969z193bz4383z9dc2z6168e3b684e3
Usmani, S. U. R., Kazmi, S. Z., Sultan, S. M. M. B., Iqbal, A., Ahmad, Z., Malik, J., & Morgan, D. M. (2026) · Journal of Perioperative Practice · doi:10.1177/17504589261440451
Abosheisha, M., Terra, M., Abdelglil, M., Ali, R. F., Elkashef, I., Ismaiel, A., Ismaiel, M., & Elemawy, M. H. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08783-2
Gurumurthy, G., Fan, B. E., Gurumurthy, J., Lippi, G., Roberts, L., Favaloro, E. J., & Thachil, J. V. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.106794
“Direct oral anticoagulants have also been investigated for use as thromboprophylaxis after orthopedic surgery [53], but their own climate foot-print is increasingly quantifiable, including pathway analyses and drug-level carbon estimates [54].”
A short history of anticoagulant therapy
Chan, N., Imiela, A. M., Carlin, S., & Hirsh, J. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109753
Davis, S. (2026) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Carl, N., Halber, E., Dempfle, C.-E. H., Löschner, D., Wies, C., Duerschmied, D., Schoettler, J. J., Beck, G., Mangold, M. H., Studier‐Fischer, A., et al. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.08.008
Soric, M. M., Chan, R., & Conger, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00990-8
Chin, A. L., & O’Connell, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00012-0
Apixaban Versus Enoxaparin For Postoperative Thromboprophylaxis
Prathap, A., Mounisha, R., Krupadevi, G., Lavanya, E., & Manisha, T. (2026) · International Journal of Enhanced Research in Medicines & Dental Care · doi:10.55948/ijermdc.13102601
BindingDB (2012) · UC San Diego · doi:10.7270/q2mk6dbs
Ahmad, M., Ahmad, A., & Aleem, R. (2026) · F1000Research · doi:10.12688/f1000research.189494.1
Mohammad, H. R., Rahman, A., Muhammad, I. M., Gill, S. S., Selim, A. A. H. A., Thomas, G., Murray, D. W., & Griffin, X. L. (2026) · The Bone & Joint Journal · doi:10.1302/0301-620x.108b11.bjj-2026-0451.r2
Anticoagulants oraux directs chez la personne âgée, point de vue de l’anesthésiste-réanimateur
Noll, É., Burgin, M., Thibaud, A., Vogel, T., Pottecher, J., & Diemunsch, P. A. (2015) · Les cahiers de l année gérontologique · doi:10.1007/s12612-015-0458-2
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.